Gan & Lee Pharmaceuticals Co., Ltd. Class A 603087

Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA formulated for once-weekly administration. This milestone marks the formal entry of this innovative candidate into clinical development.

Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results.

Gan & Lee will receive a $5m upfront payment plus up to $76.1m in milestone payments.

Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and develope

Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection, have successfully met their pre-specified primary endpoints. After 26 weeks of treatment, once-weekly GZR4 demonstrated statistically significant superior efficacy in reducing glycated hemoglobin A1c (HbA1c)* compared with once-daily insulin glargine U100 (Lantus®) and once-daily insulin degludec (Tresiba®).

Amid a backdrop of heightened global uncertainty, with U.S. equity indexes experiencing declines due to geopolitical tensions and inflation concerns, the tech sector continues to capture investor interest for its potential high growth opportunities. In such volatile times, identifying tech stocks that demonstrate strong fundamentals and adaptability to market shifts can be crucial for navigating these challenging conditions.

Emerging opportunities include advancing semaglutide in type 2 diabetes and obesity treatment, focusing on oral and injectable forms, biosimilar competition, digital adherence solutions, and robust regional strategies. Stakeholders should leverage collaboration, supply chain agility, and tailored segmentation strategies to optimize market potential.Dublin, Dec. 23, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Preparations Market - Global Forecast 2025-2030" has been added to ResearchAndMarkets.com'

As global markets experience fluctuations with hopes for interest rate adjustments, the technology sector in Asia continues to capture significant attention, particularly as Chinese stock markets show enthusiasm for domestic tech and AI despite broader economic challenges. In this context, identifying strong stocks often involves looking at companies that demonstrate resilience and innovation in rapidly evolving sectors, which can be crucial amid shifting market dynamics.